Health Care·Biotechnology·$5.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.85 | N/A | -11.27% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.85 | N/A | -11.27% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current financial performance and did not offer guidance for future quarters. They highlighted ongoing challenges in the market.
Management did not provide specific revenue guidance for the upcoming quarters.
The company acknowledged challenges in achieving profitability.
PTC Therapeutics reported a loss that was worse than expected, leading to a significant drop in stock price. Investors reacted negatively due to the lack of revenue information and guidance. The company's ongoing challenges may raise concerns about its future performance and profitability.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CENTERPOINT ENERGY I
May 5, 2017